El-Battrawy, IbrahimNuñez-Gil, Ivan JAbumayyaleh, MohammadEstrada, VicenteManuel Becerra-Muñoz, VíctorUribarri, AitorFernández-Rozas, InmaculadaFeltes, GiselaArroyo-Espliguero, RamónTrabattoni, DanielaLópez-País, JavierPepe, MartinoRomero, RodolfoCastro-Mejía, Alex FCerrato, EnricoCapel Astrua, ThamarD'Ascenzo, FabrizioFabregat-Andres, OscarSignes-Costa, JaimeMarín, FranciscoBuonsenso, DaniloBardají, AlfredoJesús Tellez, MaríaFernández-Ortiz, AntonioMacaya, CarlosAkin, Ibrahim2023-02-092023-02-092021-08-19http://hdl.handle.net/10668/18392A systematic analysis of concomitant arterial hypertension in COVID-19 patients and the impact of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) have not been studied in a large multicentre cohort yet. We conducted a subanalysis from the international HOPE Registry (https://hopeprojectmd.com, NCT04334291) comparing COVID-19 in presence and absence of arterial hypertension. Out of 5837 COVID-19 patients, 2850 (48.8%) patients had the diagnosis arterial hypertension. 1978/2813 (70.3%) patients were already treated with ACEI or ARBs. The clinical outcome of the present subanalysis included all-cause mortality over 40 days of follow-up. Patients with arterial hypertension suffered significantly more from different complications including respiratory insufficiency (60.8% vs 39.5%), heart failure (9.9% vs 3.1%), acute kidney injury (25.3% vs 7.3%), pneumonia (90.6% vs 86%), sepsis (14.7% vs 7.5%), and bleeding events (3.6% vs 1.6%). The mortality rate was 29.6% in patients with concomitant arterial hypertension and 11.3% without arterial hypertension (P  The mortality rate and in-hospital complications might be increased in COVID-19 patients with a concomitant history of arterial hypertension. The history of ACEI or ARBs treatments does not seem to impact the outcome of these patients.enCOVIDhypertensionAcute Kidney InjuryAge FactorsAgedAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntiviral AgentsCOVID-19CreatinineFemaleGermanyHeart FailureHospital MortalityHumansHypertensionItalyL-Lactate DehydrogenaseMaleMiddle AgedMultivariate AnalysisNoninvasive VentilationPneumoniaProportional Hazards ModelsRegistriesRespiration, ArtificialRespiratory InsufficiencySARS-CoV-2SepsisSeverity of Illness IndexSpainresearch article34409593open access10.1111/eci.135821365-2362PMC8420356https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420356https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420356/pdf